Why I’d buy FTSE 100 star Legal & General Group plc as profits set to hit record high

Roland Head explains why Legal & General Group plc (LON:LGEN) is one of his top FTSE 100 (INDEXFTSE:UKX) picks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shareholders of insurance and investment manager Legal & General Group (LSE: LGEN) have doubled their money over the last five years, when dividends are included.

That compares very well to the 23% return (plus dividends) provided by the FTSE 100 over the same period. I’m not surprised that fund manager Neil Woodford has made the stock a top three holding in both of his income funds.

Strong progress in all areas

According to chief executive Nigel Wilson, the firm is on course to deliver “a record year for earnings and profits”.

Legal & General’s retirement business has increased its market share over the last year and has a substantial pipeline of new work. The group’s investment management arm had seen net inflows of £38.1bn by the end of October, while the growth Capital business had generated £256m of gross proceeds from £821m of transactions.

Is it too late to buy?

After delivering average earnings growth of 11.5% per year since 2011, you might expect Legal & General shares to be priced for success. But the group still has a relatively modest valuation, in my view.

Today’s trading statement appeared to confirm broker forecasts for record profits in 2017. According to the data service I use, the group is expected to report an adjusted net profit of £1,491m and earnings of 25.2p per share this year.

That leaves the stock on a forecast P/E of 10.5, with a prospective yield of 5.8%. The firm’s dividend has been covered robustly by earnings and cash generation in recent years, and I’d expect this to continue this year.

I think these shares continue to rate as a long-term income buy.

A stock I’d buy and forget

The largest holding in both of Neil Woodford’s income funds is FTSE 100 pharmaceutical giant AstraZeneca (LSE: AZN).

The stock market performance of this Anglo-Swedish group has been volatile over the last couple of years, thanks to a wave of patent expiries, an unsuccessful takeover bid, and a major drug trial disappointment.

However, this is a long-term business. I believe the group’s fortunes are now starting to turn. Indeed, my feeling is that a new uptrend may have been established for the shares, which have now gained 5% this year.

AstraZeneca’s financial results certainly seem to be improving. Operating profit for the first nine months of the year rose to $2,991m. That’s an increase of 16% from last year, excluding exchange rate gains.

Patent expiries have caused the prices of several major products to fall. But this impact is starting to fade away. The group’s sales fell by 4% during the first nine months of the year, but rose by 9% during the third quarter.

Analysts’ expect the group to report adjusted earnings of $3.79 per share this year, providing solid cover for the expected dividend of $2.73 per share.

These figures give the stock a forecast P/E of 16.7 and a prospective yield of 4.3%. In my opinion, this could be a good entry point for long-term income investors.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »